Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12470270 | 0.93 | RORC (0.79) | RORCCYP3A4 | |
| SCHEMBL12471425 | 0.93 | RORC (0.78) | RORCCYP3A4 | |
| SCHEMBL12470581 | 0.90 | RORC (0.82) | RORC | |
| SCHEMBL15567131 | 0.87 | RORC (0.62) | RORC | |
| SCHEMBL12470659 | 0.86 | RORC (0.77) | RORCCYP3A4 | |
| SCHEMBL12471422 | 0.85 | RORC (0.68) | RORCCYP3A4 | |
| SCHEMBL15567130 | 0.84 | RORC (0.67) | RORCCYP3A4 | |
| SCHEMBL15453653 | 0.84 | RORC (0.72) | RORCCYP3A4 | |
| SCHEMBL12470454 | 0.83 | RORC (0.63) | RORCCYP3A4 | |
| SCHEMBL12470489 | 0.83 | RORC (0.69) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683693-B1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | claimed |
| US-9603838-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | claimed |
| US-20150297566-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2015-10-22 | — | — | US | claimed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | claimed |
| EP-2683693-A1 | RORGAMMAT INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-01-15 | — | — | EP | claimed |
| WO-2012106995-A1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-16 | — | — | WO | claimed |
| US-9884043-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170340610-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2017-11-30 | — | — | US | disclosed |
| EP-2683693-B1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9603838-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150297566-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2015-10-22 | — | — | US | disclosed |
| US-9095583-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| EP-2683693-A1 | RORGAMMAT INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012106995-A1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297566-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | RORC 2/4885CYP3A4 2096/4885 |
| US-20170340610-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | RORC 2/4885CYP3A4 2137/4885 |
| US-20140038942-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | RORC 2/4885CYP3A4 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.